Vilip 50 mg (Tablet)

Unit Price: ৳ 19.00 (3 x 10: ৳ 570.00)
Strip Price: ৳ 190.00

Medicine Details

Category Details
Generic Vildagliptin
Company Team pharmaceuticals ltd

Product Title

  • Vilip Tablets

Categories

  • Medicine
  • Diabetes Management

Description

  • Vilip is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy and in dual combination with other antidiabetic agents when diet and exercise alone do not suffice.

Dosage Options

  • 50 mg or 100 mg daily for monotherapy
  • 50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione
  • 50 mg once daily in the morning when used in dual combination with a Sulphonylurea

Pharmacological Action

  • Dipeptidyl Peptidase-4 (DPP-4) inhibitor
  • Slows the inactivation of incretin hormones
  • Increases insulin release and decreases glucagon levels in a glucose-dependent manner

Interaction

  • No interactions with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan or simvastatin observed
  • Glucose-lowering effect may be reduced by certain active substances such as thiazides, corticosteroids, thyroid products, and sympathomimetics

Contraindications

  • Hypersensitivity to the active substance or excipients
  • Moderate to severe renal impairment
  • Hepatic impairment: patients with pre-treatment ALT or AST >3 times the upper limit of normal (ULN)
  • Type 1 diabetes

Side Effects

  • Majority of adverse reactions are mild and transient
  • Rare cases of hepatic dysfunction reported
  • No additional safety signals identified in clinical trials of up to and more than 2 years duration

Pregnancy & Lactation

  • Not to be used during pregnancy
  • Not to be used during lactation

Precautions & Warnings

  • Caution in patients aged 75 years and older
  • Monitoring of LFTs prior to initiation of Vilip and at three-monthly intervals in the first year
  • Discontinue if transaminase levels are significantly increased
  • Do not reinitiate treatment after withdrawal due to liver abnormalities
  • Use with caution in patients with congestive heart failure of NYHA functional class I-II
  • Avoid in patients with NYHA functional class III IV

Therapeutic Class

  • Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

  • Store below 30°C
  • Keep away from light and moisture
  • Keep out of reach of children

Related Brands